Table 2 Blood lipid levels and lipid-lowering strategies of the sister
Date | TC | LDL-C | Lp(a) | Lipid-lowering strategies | Notes |
|---|---|---|---|---|---|
6-24-2020 | 14.31 | 11.85 | Â | evolocumab 420Â mg SC | baseline levels without any medication |
6-30-2020 | 11.66 (−18.5%) | 9.76 (−17.6%) | 112 |  | 6 days after evolocumab 420 mg |
7-7-2020 | 11.5 (−19.6%) | 9.71 (−18.1%) |  |  | 13 days after evolocumab 420 mg |
7-14-2020 | 11.87 (−17.0%) | 11.27 (−4.9%) |  | rosuvastatin 20 mg qd ezetimibe 10 mg qd | 20 days after evolocumab 420 mg |
7-29-2020 | 7 (−51.1%) | 4.65 (−60.8%) | 136.6 (+ 22.0%) | rosuvastatin 20 mg qd ezetimibe 10 mg qd |  |
8-22-2020 | 5.62 (−60.8%) | 3.67 (−69.0%) | 113.3 (+ 1.2%) | rosuvastatin 20 mg qd ezetimibe 10 mg qd |  |
9-12-2020 | Â | Â | Â | evolocumab 140Â mg SC rosuvastatin 20Â mg qd ezetimibe 10Â mg qd | Â |
10-12-2020 | 6.6 (−53.9%) | 4.39 (−63.0%) | 95.7 (−14.6%) | rosuvastatin 20 mg qd ezetimibe 10 mg qd |  |
10-14-2020 | Â | Â | Â | evolocumab 140Â mg SC rosuvastatin 20Â mg qd ezetimibe 10Â mg qd probucol 0.5Â g bid | Â |
10-24-2020 | 4.94 (−65.5%) | 3.15 (−73.4%) | 90.5 (−19.2%) | rosuvastatin 20 mg qd ezetimibe 10 mg qd probucol 0.5 g bid | 10 days after evolocumab 140 mg |
10-28-2020 | Â | Â | Â | evolocumab 140Â mg SC rosuvastatin 20Â mg qd ezetimibe 10Â mg qd probucol 0.5Â g bid | Â |
11-28-2020 | 5.46 (−61.8%) | 3.85 (−67.5%) | 90.2 (−34%) | rosuvastatin 20 mg qd ezetimibe 10 mg qd probucol 0.5 g bid |  |
3-13-2021 | 6.28 (−56.1%) | 4.56 (−61.5%) | 89.4 (−20.2%) | rosuvastatin 20 mg qd ezetimibe 10 mg qd probucol 0.5 g bid |  |
4-17-2021 | 6.36 (−55.6%) | 4.46 (−62.4%) | 93 (−17.0%) | rosuvastatin 20 mg qd ezetimibe 10 mg qd probucol 0.5 g bid |  |